The only thing i can guess at is that mgmt is as quiet as ever and is only releasing information because they have to for SEC reasons. The other observation is that the volume is quite low, I have no idea how but leading up to some type of news there is an increase in volume. Based on this I don't think any news is coming soon. Mgmt's silence has been explained to me to be a result of not wanting to create problems with the FDA. I think we are in the wait and see part of development. Things are getting done, but some major deal is yet to be a real event soon. I have zero clue if the R/S and uplist is a thing of the past or still on the table. I feel like months ago it was a plan to get uplisted but because the SP movement was so underwhelming after the PE PR, mgmt might be thinking why bother. Us investors and mgmt want the same thing (buyout) and being on the nasdaq might not be as appealing. Along these lines, In my opinion, 2018 is the year for some type of deal. So, why bother with the cost to uplist and all of the accounting required when the ticker CYDY might be on the nasdaq for a few months at most. The issue I see is that these deals get done when a biotech is during p2 or p3, once p3 is done and no deal has happened then the problem is how to now raise the money to commercialize the drug? The trials are very far along and will be well past halfway this year, enrollment and data from the mono is the key for the most value.
